iBio — Q1 Fiscal Year 2027 Earnings Summary

iBio, Inc. reported revenues of approximately $1.1 million for the first quarter of fiscal year 2027, ending September 30, 2026, representing a significant increase from the previous year. The company advanced its clinical pipeline by completing dosing in the single ascending dose portion of the Phase 1 trial for IBIO-600 and presenting new preclinical data showing that IBIO-610 combined with semaglutide resulted in 93% of weight loss coming from fat in non-human primates. Operating expenses rose to $9.4 million due to increased spending on consultants, outside services, and personnel costs associated with advancing multiple programs. As of September 30, 2026, iBio held $76.7 million in cash, cash equivalents, and investments in debt securities while reporting a net loss of $7.6 million for the quarter.